Teva’s generic to Gilead’s blockbuster AIDS treatment and prevention drug, Truvada, could launch as early as 2020, according to a newly filed agreement between the two companies. The generic copy originally wasn’t expected to launch until 2021. In the pharmacy benefit, Truvada currently holds preferred status for 64% of covered lives. The Department of Justice is currently investigating the legitimacy of Gilead’s patent for Truvada, but Gilead said its new agreement is not related to that activity.

SOURCE: MMIT Analytics, as of 5/14/19